The Daily Ledger

HealthNews

Lilly's Foundayo pill cuts sleep apnea severity in trial

A JAMA-published trial found Eli Lilly's daily obesity pill Foundayo reduced obstructive sleep apnea severity after 52 weeks, with Lilly planning an FDA filing by end of 2026.

The Daily Ledger Staff · Updated 3 min read

A daily weight-loss pill from Eli Lilly has shown a significant benefit for people with obstructive sleep apnea, according to new clinical trial data reported by Scientific American on 9 November 2026.

What the trial found

The drug, sold as Foundayo and known generically as orforglipron, is an oral GLP-1 treatment for obesity. The US Food and Drug Administration approved it for obesity in April. The new results, published in the Journal of the American Medical Association, found that it significantly improved obstructive sleep apnea (OSA) after 52 weeks of treatment.

Participants were classified as overweight or as having obesity. Those who did not use a positive airway pressure (PAP) machine saw a 43.8% reduction in the severity of their sleep apnea. Those who did use a PAP machine saw a 27.5% reduction. Both groups lost about 28 pounds on average.

About sleep apnea

OSA involves pauses in airflow to the lungs that last longer than 10 seconds during sleep. Symptoms include loud snoring, choking, sleep deprivation and headaches. Because the condition causes drops in blood oxygen levels, it can raise the risk of heart problems.

The scale of the condition is large. Up to 936 million adults worldwide are estimated to have it, although most are never formally diagnosed.

Expert reaction

Daniel Drucker, an endocrinologist at the Lunenfeld-Tanenbaum Research Institute in Ontario, was not involved in the trial and has previously consulted for Eli Lilly. He said that "Every time we tinker with the GLP-1 backbone, the question of overall safety and cardiovascular safety resurfaces." He suggested Foundayo may have cardiovascular benefits, and said the results add to evidence that Lilly's injectable GLP-1 medications may help with OSA. If approved for the condition, he indicated, orforglipron could offer a once-daily option.

Vaishnavi Kundel, an associate professor of medicine at the Icahn School of Medicine at Mount Sinai, co-authored the study and has also consulted for Eli Lilly. In a company statement, she said that "Foundayo significantly reduced breathing interruptions and drops in oxygen during sleep." She added that the drug also improved blood pressure and inflammation.

What happens next

Eli Lilly plans to submit Foundayo to the FDA by the end of 2026 for moderate to severe OSA in adults who are overweight or have obesity. Until a regulator reviews that application, the pill is approved only for obesity.

The findings are notable because many people with sleep apnea depend on PAP machines, and the trial suggests the pill added benefit even for those already using one. Several of the experts quoted have financial ties to the manufacturer, a point worth bearing in mind when weighing the commentary, while the trial results themselves were published in a peer-reviewed journal.

As with other drugs in the GLP-1 class, questions about long-term safety remain part of the discussion, and Drucker's remarks reflect that caution. For now, the data point to a promising new option for patients whose breathing problems are linked to excess weight.

Sources

Written with automated tools from the sources above and published without editor review. Spotted an error? Tell us · Corrections Policy

Report a problem with this story · Copyright & takedown